News | June 10, 2014

Chemo-radionuclide Therapy Halts Neuroendocrine Cancer

Combined chemo and radionuclide therapy with radiosensitizing drugs slows or stops disease progression and leads to better patient survival

June 10, 2014 — Advanced cancer of the neuroendocrine system can lead to dismal prognoses, but a novel therapy is packing a punch by uniting powerful radionuclide treatment and chemotherapy drugs, revealed researchers at the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting.

The research findings show that the experimental therapy led to stabilization or regression of patients’ cancer in about 70 percent of cases a year after completion of the treatment, now called peptide receptor chemo-radionuclide therapy (PRCRT). The therapy is just catching on across Europe and Australia and now in U.S. clinical trials. 

“Results of this study suggest that PRCRT is a highly effective treatment option for patients with progressive NETs with high somatostatin receptor expression,” explained Grace Kong, MBBS, principal investigator for this study conducted at the Centre for Cancer Imaging, Peter MacCallum Cancer Centre in Melbourne, Australia.

Neuroendocrine tumors (NETs) are those that develop within a multiplicity of organs throughout the body that have nerve cells and interact with the endocrine system through chemical signaling made possible with various hormones. These tumors usually develop along the intestines and lungs, but they can also be found in the pancreas and many other sites, although rarely. For this study, researchers observed patients who had undergone at least three courses of treatment with Lutetium-177 DOTA-Octreotate, which is prescribed for inoperable patients with NETs expressing somatostatin hormone receptors. This study included a high proportion of grade two disease, which is more aggressive and associated with adverse prognosis. Researchers added a radio-sensitizing chemotherapy for 63 out of the 68 patients in the study.

All of these steps together produced encouraging responses in a majority of subjects, with 72 percent survival at two years. More than half of patients were still alive past the five-year mark after therapy.

“The high objective response and long median survival even in patients with more aggressive tumor biology warrant further studies comparing it with other targeted therapies recently approved, despite much lower response rates,” Kong added.

For more information: www.snmmi.org

Related Content

Elekta and Brainlab Offer Streamlined Workflow for Stereotactic Radiotherapy
News | Radiation Therapy | October 16, 2017
Elekta and Brainlab have reconfirmed their alliance for the integrated use of the Elekta Versa HD linear accelerator...
National Breast Center Founder Names Top Three Innovations in Breast Cancer Treatment
News | Women's Health | October 11, 2017
In 2017, invasive breast cancer will be diagnosed in about 252,710 women and 2,470 men in the U.S. and remains the...
CyberKnife System Provides Excellent Long-Term Control of Low-Risk Prostate Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | October 10, 2017
Accuray Inc. announced that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent...
News | Image Guided Radiation Therapy (IGRT) | October 10, 2017
Elekta announced that members of the Elekta MR-linac Consortium reported data related to the advancement of the company...
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
Benjamin Movsas, M.D., chair of the American Society for Radiation Oncology (ASTRO) Scientific Committee, explains ho
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
David Beyer, M.D., chairman of the board for the American Society of Radiation Oncology (ASTRO), discusses the key th
News | Brachytherapy Systems | October 05, 2017
External researchers presented new clinical data supporting the use of iCAD’s Xoft Axxent Electronic Brachytherapy (eBx...
MedLever Showcases Radiation Oncology Applications at ASTRO 2017
News | Radiation Therapy | October 05, 2017
MedLever demonstrated its flagship platform and applications that simplify clinical workflow, enable interoperability,...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
International Trial Confirms Safety, Effectiveness of High-Dose Brachytherapy Plus Pelvic Radiation for Cervical Cancer
News | Brachytherapy Systems, Women's Healthcare | October 04, 2017
Findings from a new multicenter, international clinical trial confirm the effectiveness of high-dose brachytherapy or...
Overlay Init